P5(PEG24)-VC-PAB-Exatecan

Overview

P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab ( HY-P9907 ) generates a DAR8 antibody-drug conjugate ( ADCs ) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns ( DAMP ) related to immunogenic cell death ( ICD ). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers.

Application

Products | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > HER2-Positive Gastric Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Antibody-Drug Conjugate/ADC Related | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Drug-Linker Conjugates for ADC | Products > Signaling Pathways > Topoisomerase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-163099
• CAS No.: 2928571-43-9
• Molecular Formula: C100H151FN9O36P
• Molecular Weight: 2105.28
• Purity: 98.59%
• Storage: -20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
• Availability: In-stock

Source

Original product source